GLP-1 Cost Index 2026: What Every Drug Costs Monthly

The GLP-1 cost in 2026 ranges from about $129 a month to over $1,300, for what is often the same active ingredient. Branded list prices cluster between roughly $997 and $1,349 per month, but almost nobody pays that: insurance, manufacturer self-pay programs, savings cards, and compounded telehealth all pull the real GLP-1 cost far lower. This page is a single reference for what every major GLP-1 medication costs per month in 2026, across every payment route, so you can compare them side by side instead of chasing one drug at a time.

GLP-1 cost by the numbers (2026)

• ~$997 to $1,349 per month: the branded list-price range across the six major GLP-1 medications.
• ~$1,130 per month: the rough average branded list price before any discount.
• $349 to $499 per month: the cheapest predictable branded cash route (manufacturer self-pay vials).
• From ~$129 per month: the lowest overall GLP-1 cost, via compounded semaglutide or tirzepatide prescribed online.
• $0 to $100 per month: a typical copay when insurance covers the drug; a savings card can push covered costs toward $25.

In other words, the gap between the highest and lowest GLP-1 cost for a comparable course of treatment is more than tenfold, and which number you land on depends almost entirely on your route, not the medication.

The GLP-1 cost index: every drug, every route

The table below is the core of this index. It lists each major GLP-1 (and dual GIP/GLP-1) medication, its active ingredient and approved use, the monthly list price, and the lowest realistic price on each route. All figures are approximate, change frequently, and should be confirmed with the manufacturer or pharmacy before you rely on them.

Medication	Active ingredient	Approved use	List price / mo	Manufacturer self-pay	With insurance
Wegovy	Semaglutide	Weight management	~$1,349	NovoCare cash ~$499	$0–$100 copay; savings card lower
Ozempic	Semaglutide	Type 2 diabetes	~$997	No dedicated cash-vial program	$0–$100 copay; savings card lower
Rybelsus	Semaglutide (oral)	Type 2 diabetes	~$997	No dedicated cash-vial program	$0–$100 copay; savings card lower
Zepbound	Tirzepatide	Weight management	~$1,086	LillyDirect vials $349–$499	$0–$100 copay; savings card lower
Mounjaro	Tirzepatide	Type 2 diabetes	~$1,069	No dedicated cash-vial program	$0–$100 copay; savings card lower
Saxenda	Liraglutide	Weight management	~$1,349	No dedicated cash-vial program	$0–$100 copay; savings card lower
Compounded	Semaglutide / tirzepatide	Via telehealth, case-by-case	n/a (not branded)	From ~$129–$199 all-in	Usually cash, no insurance

The single biggest driver of the real GLP-1 cost is not the drug but whether you are insured and which program you qualify for. Two people on the same molecule can pay $25 and $1,086 in the same month.

Branded list prices: the number almost nobody pays

The list price is the manufacturer's pre-discount sticker, and it anchors a system most patients never touch directly. As of early 2026, the semaglutide weight drug Wegovy and the liraglutide drug Saxenda sit highest at around $1,349 a month, the tirzepatide drugs Zepbound and Mounjaro run about $1,069 to $1,086, and the diabetes semaglutide products Ozempic and Rybelsus are near $997. These figures appear on insurance paperwork and in policy debates far more often than on patient receipts. For the brand-by-brand detail, see our cost pages for Ozempic, Wegovy, and Zepbound and Mounjaro.

What an uninsured patient actually pays is layered: the list price is the ceiling, and the floor depends on which programs you qualify for and how much logistics you will manage. Our full guide to lowering the cost of GLP-1 medications walks through every route in order.

With insurance: the cheapest outcome, if you can get it

When a plan covers a GLP-1, the GLP-1 cost drops to a copay, often $0 to $100 for a 28-day supply. That is the lowest figure available, and it is worth pursuing first. The obstacle is that many U.S. plans still exclude anti-obesity medications, covering the same molecule readily for a diabetes diagnosis but not for weight management. Coverage usually hinges on prior authorization and the plan's formulary, which we cover in getting GLP-1 covered by insurance and, for older adults, does Medicare cover GLP-1. A manufacturer savings card can lower a commercially insured GLP-1 cost further, toward $25 for those whose plan covers the drug.

Manufacturer self-pay: the cheapest branded route

For uninsured patients, the manufacturers built cash channels that bring the branded GLP-1 cost down sharply. Eli Lilly's LillyDirect sells Zepbound single-dose vials from about $349 (2.5 mg) to $499 (5 mg) a month, and Novo Nordisk's NovoCare pharmacy offers cash Wegovy in the same broad range. These are the cheapest predictable branded prices, straight from the maker, so sourcing is not in question. The diabetes brands have no equivalent dedicated cash-vial program, so uninsured diabetes patients lean on savings cards, discount cards, and patient assistance instead.

Compounded telehealth: the lowest GLP-1 cost overall

The lowest GLP-1 cost in the index does not come from a brand at all. Compounded semaglutide or tirzepatide, prescribed through a licensed telehealth clinician and dispensed by a compounding pharmacy, has brought the monthly cost down to roughly $129 to $199, typically bundling the visit, prescription, and delivery into one cash price. That is why so many uninsured patients take this route, detailed in compounded GLP-1 online and best telehealth GLP-1 prescriptions.

Two honest caveats belong in any cost index. First, compounded GLP-1s are legally narrower than they were during the 2024 shortage, so they require a real prescription from a clinician who has evaluated you, not a blanket discount. Second, quality depends entirely on the pharmacy: a credentialed 503A or 503B facility with tested ingredients is a different thing from a grey-market peptide seller. The lowest GLP-1 cost is only a real saving when it is also safe.

Methodology and sources

Prices in this index are the U.S. monthly figures most commonly reported as of early 2026, drawn from manufacturer pricing programs (LillyDirect, NovoCare), published cost analyses, and the brand cost pages maintained on this site. List prices are 28-day wholesale figures before rebates; self-pay and compounded figures are the lowest commonly advertised monthly prices, which vary by dose, pharmacy, and region. GLP-1 pricing moves frequently, so treat every number as a current estimate and verify with the manufacturer or pharmacy before acting. For how the drugs themselves compare, see semaglutide versus tirzepatide and the full GLP-1 medications list.

What is pushing the GLP-1 cost down

For the first two years of the GLP-1 weight-loss era, the only number most uninsured patients saw was the four-figure list price. That has changed quickly, and the GLP-1 cost is now trending downward on several fronts at once. Manufacturers launched direct cash channels in 2024 and 2025, with Lilly's LillyDirect vials and Novo Nordisk's NovoCare cash pricing cutting the branded self-pay cost by roughly half. Telehealth platforms built compounded routes that undercut the brands further, and even as compounding narrowed after the shortage ended, competition kept the cash GLP-1 cost near $129 to $199 for many patients.

Looking ahead, three forces are likely to keep pressure on the GLP-1 cost through 2026 and beyond: more once-weekly and oral entrants reaching the market, growing payer scrutiny that is slowly expanding coverage for obesity as a treated condition rather than a lifestyle issue, and the eventual arrival of lower-cost competition as early patents face challenges. None of this makes a GLP-1 cheap overnight, but the direction is clear, and the spread between the list price and what an informed patient actually pays has never been wider. Knowing the routes in this index is, for now, worth more than waiting for prices to fall on their own.